Cargando…

Correction Notice: Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208877/ https://www.ncbi.nlm.nih.gov/pubmed/35747842 http://dx.doi.org/10.1097/HS9.0000000000000731

Ejemplares similares

Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies
por: Petzer, Verena, et al.
Publicado: (2022)

Correction: Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies
por: Duhoux, Francois P., et al.
Publicado: (2011)

Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study “Cervax”
por: Mohamed, Sara, et al.
Publicado: (2023)

Notice of Correction
Publicado: (2019)

Correction notice
por: Samardžija, M., et al.
Publicado: (2021)

Serological Responses and Predictive Factors of Booster COVID-19 Vaccines in Patients with Hematologic Malignancies
por: Huang, Chien-Tzu, et al.
Publicado: (2023)

A notice of correction
Publicado: (2012)

Author Correction: Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England
por: Amirthalingam, Gayatri, et al.
Publicado: (2022)

Correction Notice
Publicado: (2017)

Correction Notice
Publicado: (2017)

Correction Notice
Publicado: (2019)

Correction Notice
Publicado: (2022)

Correction notice
Publicado: (2022)

Correction notice
Publicado: (2022)

History of Autologous SCT Does Not Appear to Blunt the Serologic Response to COVID-19 Vaccination for Patients with Lymphoid Malignancies
por: Djulbegovic, Mia, et al.
Publicado: (2022)

Correction Notice – Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study
Publicado: (2023)

Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer
por: Fendler, Annika, et al.
Publicado: (2022)

COVID Vaccine Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Better Antibody Response in Patients with Myeloid Malignancies Than B-Cell Malignancies
por: Goksu, Suleyman Y, et al.
Publicado: (2021)

Correction to: Patterns of bone marrow aspiration confirmed hematological malignancies in Eritrean National Health Laboratory
por: Belai, Natnael, et al.
Publicado: (2019)

Correction: Dietary restriction improves repopulation but impairs lymphoid differentiation capacity of hematopoietic stem cells in early aging
por: Tang, Duozhuang, et al.
Publicado: (2020)

Homoharringtonine and omacetaxine for myeloid hematological malignancies
por: Lü, Shuqing, et al.
Publicado: (2014)

MicroRNAs in Myeloid Hematological Malignancies
por: Ciccone, Maria, et al.
Publicado: (2015)

Author Correction: A practical guide for mutational signature analysis in hematological malignancies
por: Maura, Francesco, et al.
Publicado: (2019)

Correction Notice: The EHA Research Roadmap: Anemias
Publicado: (2021)

Decoding the Myeloid-Derived Suppressor Cells in Lymphoid Malignancies
por: Papafragkos, Iosif, et al.
Publicado: (2021)

2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.
por: Hickish, T., et al.
Publicado: (1993)

Correction Notice—The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action
Publicado: (2023)

Correction to: Functional classification of RUNX1 variants in familial platelet disorder with associated myeloid malignancies
por: Decker, Melanie, et al.
Publicado: (2022)

Author Correction: Differentiating central nervous system infection from disease infiltration in hematological malignancy
por: Lim, Emma A., et al.
Publicado: (2022)

Serologic Responses Following Sars-Cov-2 Vaccination and Factors Influencing It in Patients with Hematological Malignant and Non-Malignant Diseases - a Prospective Multicentric Study
por: Sertić, Zrinka, et al.
Publicado: (2021)

IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
por: Parrondo, Ricardo D., et al.
Publicado: (2023)

T-cell-predominant lymphoid hyperplasia in a tattoo
por: Souza, Erica Sales, et al.
Publicado: (2014)

Correction Notice: Antifungal Prophylaxis in Acute Myeloid Leukemia: New Drugs, New Challenges? Summary of the EHA Guideline on Antifungal Prophylaxis in Adult Patients With Acute Myeloid Leukemia Treated With Novel-targeted Therapies
Publicado: (2022)

Author Correction: Artificial Intelligence based Models for Screening of Hematologic Malignancies using Cell Population Data
por: Syed-Abdul, Shabbir, et al.
Publicado: (2020)

Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma
por: Akhtar, Saad, et al.
Publicado: (2021)

Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies
por: Palumbo, Giuseppe Alberto, et al.
Publicado: (2019)

Author Correction to: T-lymphoid progenitor-based immunotherapies: clinical perspectives for one and all
por: Gaudeaux, P., et al.
Publicado: (2022)

Correction: Development of Models for Predicting the Predominant Taste and Odor Compounds in Taihu Lake, China
por: Qi, Min, et al.
Publicado: (2013)

Correction Notice: Low-risk Essential Thrombocythemia: A Comprehensive Review
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7jt6uhvnis4a5thdhg6luvdb50